Buparlisib (BKM120) is a pan-class I PI3K inhibitor that showed modest efficacy and was tolerable in advanced acute leukemias (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) [94]. Here, PIK3CD is linked to acute myeloid leukemia.